Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial
Bertini E, Dessaud E, Mercuri E, Muntoni F, Kirschner J, Reid C, Lusakowska A, Comi GP, Cuisset JM, Abitbol JL, Scherrer B, Ducray PS, Buchbjerg J, Vianna E, van der Pol WL, Vuillerot C, Blaettler T, Fontoura P; Olesoxime SMA Phase 2 Study Investigators
Lancet Neurol. 2017. 16(7):513-522.
This phase 2 randomised, double-blind, placebo-controlled study was done in 22 neuromuscular care centres from 7 european country aimed to study safety and efficacy of olesoxime in patients aged 3-25 years with type 2 or type 3 SMA.
The primary outcome measure was change from baseline compared with 24 months of MFM D1+D2 scores.
Olesoxime seemed to be safe and generally well tolerated at the doses studied. Results suggested that olesoxime might maintain motor function in patients with type 2 or type 3 SMA over a period of 24 months
Keywords: Spinal Muscular atrophy, Phase 2, Safety, Olesoxime
Articles dans les revues scientifiques
Rasch analysis to evaluate the motor function measure for patients with facioscapulohumeral muscular dystrophy
Mul K, Horlings CGC, Faber CG, van Engelen BGM, Merkies ISJ. Int J Rehabil Res. 2021. 1;44(1):38-44. A Rasch analyses was performed on MFM data from 194 FSHD patients to assess clinimetric properties in this patient group.Rasch analysis revealed multiple limitations...
Assessment of the validity and reliability of the 32-item Motor Function Measure in individuals with Type 2 or non-ambulant Type 3 spinal muscular atrophy
Trundell D, Le Scouiller S, Le Goff L, Gorni K, Vuillerot C. PLoS One. 2020 Sep 18;15(9):e0238786. Cette étude visait à examiner la fiabilité, la validité et la capacité à détecter les changements de la MFM32 chez des sujets atteints d'Amyotrophie Spinale Infantile...
Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen
Gómez-García de la Banda M, Amaddeo A, Khirani S, Pruvost S, Barnerias C, Dabaj I, Bénézit A, Durigneux J, Carlier RY, Desguerre I, Quijano-Roy S, Fauroux B. Pediatr Pulmonol. 2021. 56(1):299-306. La performance des muscles respiratoires et la fonction pulmonaire ont...
Association Between Health-Related Quality of Life and Motor Function in Ambulant and Nonambulant Duchenne Muscular Dystrophy Patients
Gocheva V, Schmidt S, Orsini AL, Hafner P, Schaedelin S, Rueedi N, Weber P, Fischer D. J Child Neurol. 2019. 34(14):873-885. Étude transversale évaluant la qualité de vie liée à la santé (HRQOL) chez des patients ambulants et non ambulants atteints de dystrophie...
Validity and Reliability of the 32-Item Motor Function Measure in 2- to 5-Year-Olds with Neuromuscular Disorders and 2- to 25-Year-Olds with Spinal Muscular Atrophy
Trundell D, Le Scouiller S, Gorni K, Seabrook T, Vuillerot C, SMA MFM Study Group. Neurol Ther. 2020. 9(2):575-584. Étude de la validité et de la fiabilité de la MFM32 chez des personnes atteintes de maladies neuromusculaires, y compris d’amyotrophie spinale infantile...
Health-related quality of life, self-reported impairments and activities of daily living in relation to muscle function in post-polio syndrome
Gocheva V, Hafner P, Orsini AL, Schmidt S, Schaedelin S, Rueedi N, Rubino-Nacht D, Weber P, Fischer D. J Patient Rep Outcomes. 2020. 16;4(1):59. Étude de la qualité de vie liée à la santé (HRQOL), des déficiences autodéclarées et des activités de la vie quotidienne et...